News & Updates
Showing Pharmacy articles
Showing
Sitra + nivo slightly better than docetaxel in advanced NSCLC
Treatment with sitravatinib plus nivolumab (sitra + nivo) results in numerically longer median overall survival (OS), albeit statistically nonsignificant, in patients with advanced nonsquamous nonsmall-cell lung cancer (NSCLC) compared with docetaxel, a study has shown.
Sacituzumab govitecan makes case as third-line therapy in mTNBC
Third-line treatment with sacituzumab govitecan works better than the physician’s treatment of choice in metastatic triple-negative breast cancer (mTNBC), an invasive histologic subtype with a poor prognosis and rapid progression, as shown in a recent study.
Erdafitinib prevents recurrence in high-risk NMIBC
Recurrence-free survival (RFS) is significantly longer with erdafitinib treatment than with intravesical chemotherapy in patients with papillary-only, high-risk nonmuscle-invasive bladder cancer (NMIBC) who had disease recurrence after bacillus Calmette–Guérin (BCG) therapy and were ineligible for radical cystectomy, according to a study.
Amivantamab plus chemo improves survival in advanced NSCLC
Amivantamab plus chemotherapy with or without lazertinib results in longer progression-free survival (PFS), as well as intracranial PFS, compared with chemotherapy alone in patients with epidermal growth factor receptor (EGFR)-mutated advanced nonsmall-cell lung cancer (NSCLC) who had disease progression on or after osimertinib, results of the phase III MARIPOSA-2 study have shown.
Shorter antibiotic dosing for pneumonia holds up against usual care in Asians
In the treatment of Asian patients with ventilator-associated pneumonia (VAP), shortened antibiotic treatment duration guided by clinical response compares favourably with longer treatment durations used in usual care in terms of 60-day mortality and pneumonia recurrence, as shown in the open-label REGARD-VAP trial.